Fourth Department of Medicine, Charité University Hospital, Berlin, Germany.
Inflamm Bowel Dis. 1997 Fall;3(3):204-16.
: Anemia in patients with inflammatory bowel disease (IBD) is caused in more than 80% of cases by iron and/or vitamin deficiency. In single cases hemolysis or myelosuppression occurs. The exact mechanisms are unknown. In the remaining patients (10-20%), substitution treatment does not improve anemia. Laboratory tests are often obscured by changes induced by the immunologic activity of the inflammatory disorder. Recent studies have demonstrated that the proinflammatory cytokines produced in IBD can suppress erythropoiesis by the inhibition of erythropoietin secretion and action. In therapeutic trials, it has been shown that coadministration of recombinant erythropoietin can substantially improve therapy in those with refractory anemia in IBD.
炎症性肠病(IBD)患者的贫血 80%以上是由铁和/或维生素缺乏引起的。在个别情况下会发生溶血或骨髓抑制。确切的机制尚不清楚。在其余的患者(10-20%)中,替代治疗并不能改善贫血。实验室检查常因炎症性疾病的免疫活性引起的变化而变得模糊。最近的研究表明,IBD 中产生的促炎细胞因子可通过抑制促红细胞生成素的分泌和作用来抑制红细胞生成。在治疗试验中,已表明联合使用重组促红细胞生成素可显著改善难治性 IBD 贫血患者的治疗效果。